Drug intelligence / Profile preview

IBIS-Influenza

Development stage: Preclinical
Lead developer: Canthevac
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intratracheal, Conjunctival, In Ovo

Overview

IBIS-Influenza is a preclinical-stage preventive vaccine candidate being developed by Canthevac for the prevention of influenza. It is part of the company's IBIS platform, which focuses on developing vaccines against various respiratory and viral pathogens. The vaccine is designed to induce protective immunity against the influenza virus to prevent infection and associated disease. As of early 2026, the candidate remains in the preclinical phase of development.

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on IBIS-Influenza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBIS-Influenza.

Explore the full profile